Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Bristol Myers Squibb
Main (gene editing) focus: Next-generation cellular therapies
Company stage: Commercial
Diseases (gene editing): Acute myeloid leukaemia (AML), multiple myeloma (MM), other haematological and solid tumours
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ:BMY)
Location: New York City, New York, USA
Gene editing partnerships: Century Therapeutics
Bristol Myers Squibb (BMS) is a big pharma company developing drugs within many different disease areas. The company is engaged in the gene-editing space through its collaboration with Century Therapeutics, which is an early stage company developing gene-edited iPSC-derived cellular therapies. Together, the two companies will develop programmes with the intent to treat acute myeloid leukaemia and multiple myeloma.